Cadorex Actions

• Cadorex pharmacology
• Cadorex reviews

Cadorex pharmacology

The pharmacokinetic disposition of Cadorex™ was evaluated in feeder calves following a single subcutaneous injection at a dose rate of 40 mg Cadorex/kg body weight. Administration of Cadorex™ resulted in Cadorex plasma concentrations of 2 µg (mcg)/mL within two hours of injection.

Table 1. Pharmacokinetic Parameter Values for Cadorex Following a Single Subcutaneous Injection of Cadorex™ at a Dose Rate of 40 mg Cadorex/kg Body Weight to Feeder Calves (n=24).

	Cmax (µg/mL)	Tmax (hr)	AUClast (µg*hr/mL)	T½ (hr)
Cmax: Maximum observed plasma concentration Tmax: Time at which Cmax was observed AUClast: Area under the plasma-concentration-time curve from time zero to the last quantifiable concentration that is equal to or greater than the limit of quantification of the validated analytical method T½: Terminal elimination half-life % CV: Percent coefficient of variance
* T½ value could not be accurately estimated for one calf † Tmax is presented as the median value or range of observed values (minimum to maximum)
n	24	24	24	23*
Mean	5.93	5†	150	37.7
% CV	38.3	2-12†	20.9	27.3

Figure 1. Mean Cadorex Plasma Concentration versus Time Following a Single Subcutaneous Injection of Cadorex™ at a Dose Rate of 40 mg Florfenico/kg Body Weight in Feeder Calves (Mean ± Standard Error of the Mean)

MICROBIOLOGY

Cadorex is a synthetic, broad-spectrum antibiotic active against many Gram-negative and Gram-positive bacteria isolated from domestic animals. It acts by binding to the 50S ribosomal subunit and inhibiting bacterial protein synthesis. Cadorex is generally considered a bacteriostatic drug, but it exhibits bactericidal activity against certain bacterial species. In vitro studies demonstrate that Cadorex is active against the BRD pathogens M. haemolytica, P. multocida, H. somni, and M. bovis and that Cadorex exhibits bactericidal activity against strains of M. haemolytica and H. somni.

The minimum inhibitory concentrations (MICs) of Cadorex were determined for BRD isolates obtained from calves enrolled in BRD field studies in the U.S. in 2006 using methods recommended by the Clinical and Laboratory Standards Institute (M31-A2). Isolates were obtained from pre-treatment nasal swabs from all calves enrolled at all four sites, post-treatment nasal swabs from treatment failures in the Cadorex Injectable Solution and saline control treatment groups at three sites, and lung tissue from one calf that died in the saline control treatment group. The results are shown below in Table 2.

Table 2. Cadorex MIC values* of indicated pathogens isolated from cattle with naturally-occurring BRD

Indicated pathogens	Year of isolation	No. of isolates	MIC50† (µg/mL)	MIC90† (µg/mL)	MIC range (µg/mL)
* The correlation between in vitro susceptibility data and clinical effectiveness is unknown. † The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.
Mannheimia haemolytica	2006	158	1.0	1.0	0.5 to 32
Pasteurella multocida	2006	103	0.5	0.5	≤ 0.125 to 16
Histophilus somni	2006	85	≤ 0.125	≤ 0.125	≤ 0.125 to 0.25

Reviews

The results of a survey conducted on ndrugs.com for Cadorex are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Cadorex. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 16 here

Information checked by Dr. Sachin Kumar, MD Pharmacology